Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: A randomised comparative trial with crossover design

Gut

Volumn 59, Issue 5, 2010, Pages 572-578

  Liou, Jyh Ming ^a,b   Lin, Jaw Town ^a,c   Chang, Chi Yang ^c   Chen, Mei Jyh ^a   Cheng, Tsu Yao ^a   Lee, Yi Chia ^a,b   Chen, Chien Chuan ^a   Sheng, Wang Huei ^a   Wang, Hsiu Po ^a   Wu, Ming Shiang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CARBON 13; CLARITHROMYCIN; LANSOPRAZOLE; LEVOFLOXACIN;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BLOATING; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RETREATMENT; STOMACH BIOPSY; TAIWAN; TASTE DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; UREA BREATH TEST; VOMITING;

ADULT; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OFLOXACIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951743890     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.198309     Document Type: Article

References (37)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-1186.
2. Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009;151:121-128.
3. Talley NJ, Fock KM, Moayyedi P. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol 2008;103:510-514.
4. Malfertheiner P, Megraud F, O'morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781.
5. Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-1825.
6. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008;5:321-331 (Pubitemid 351803603)
7. Nista EC, Candelli M, Zocco MA, et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 2006;101:1985-1990 (Pubitemid 44337620)
8. Gisbert JP, Fernández-Bermejo M, Molina-Infante J, et al. First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2007;26:495-500. (Pubitemid 47063147)
9. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008;148:923-931.
10. Zullo A, De Francesco V, Hassan C, et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007;56:1353-1357 (Pubitemid 47517826)
11. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44. (Pubitemid 43381164)
12. Saad RJ, Schoenfeld P, Kim HM, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006;101:488-496 (Pubitemid 46894012)
13. Gisbert JP, Bermejo F, Castro-Fernández M, et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 2008;103:71-76.
14. Rokkas T, Sechopoulos P, Robotis I, et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009;104:21-25.
15. Lee YC, Wu HM, Chen TH, et al. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. Helicobacter 2006;11:418-424.
16. Zullo A, Perna F, Hassan C, et al. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther 2007;25:1429-1434 (Pubitemid 46848887)
17. Hung KH, Sheu BS, Chang WL, et al. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 2009;14:61-65.
18. Calvet X, García N, López T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:603-609 (Pubitemid 30240753)
19. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752-760 (Pubitemid 37153652)
20. Shorr AF, Khashab MM, Xiang JX, et al. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir Med 2006;100:2129-2136.
21. Hadley JA. Value of short-course antimicrobial therapy in acute bacterial rhinosinusitis. Int J Antimicrob Agents 2005;26 Suppl 3:S164-9.
22. Gisbert JP. 'Rescue' regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008;14:5385-5402.
23. Chen TS, Chang FY, Chen PC, et al. Simplified 13C-urea breath test with a new infrared spectrometer for diagnosis of Helicobacter pylori infection. J Gastroenterol Hepatol 2003;18:1237-1243 (Pubitemid 37463997)
24. Koletzko S, Richy F, Bontems P, et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006;55:1711-1716 (Pubitemid 44893567)
25. Rispo A, Di Girolamo E, Cozzolino A, et al. Levofloxacin in first-line treatment of Helicobacter pylori infection. Helicobacter 2007;12:364-365 (Pubitemid 47196341)
26. Antos D, Schneider-Brachert W, Bästlein E, et al. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 2006;11:39-45.
27. Liou JM, Chen CY, Wu MS, et al. Comparative study of modified-release clarithromycin and immediate-release clarithromycin in the treatment of Helicobacter pylori-associated peptic ulcer disease. Hepatogastroenterology 2006;53:784-788.
28. Cheng HC, Chang WL, Chen WY, et al. Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy. Helicobacter 2007;12:359-363 (Pubitemid 47196332)
29. Gasbarrini A, Ojetti V, Armuzzi A, et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:79-83. (Pubitemid 30058164)
30. Chan FK, Sung JJ, Suen R, et al. Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. Aliment Pharmacol Ther 2000;14:91-95 (Pubitemid 30058166)
31. Gomollón F, Valdepérez J, Garuz R, et al. Cost-effectiveness analysis of 2 strategies of Helicobacter pylori eradication: results of a prospective and randomized study in primary care. Med Clin (Barc) 2000;115:1-6.
32. Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991e2000. Clin Infect Dis 2003;37:1643-1648 (Pubitemid 37549951)
33. Carothers JJ, Bruce MG, Hennessy TW, et al. The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 2007;44:e5-8.
34. Sheng WH, Chen YC, Wang JT, et al. Emerging fluoroquinolone-resistance for common clinically important gram-negative bacteria in Taiwan. Diagn Microbiol Infect Dis 2002;43:141-147.
35. Nikaido H. Antibiotic resistance caused by gram-negative multidrug efflux pumps. Clin Infect Dis 1998;27 Suppl 1:S32-41.
36. Liu ZQ, Zheng PY, Yang PC. Efflux pump gene hefA of Helicobacter pylori plays an important role in multidrug resistance. World J Gastroenterol 2008;14:5217-5222.
37. Cambau E, Allerheiligen V, Coulon C. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol 2009;47:3600-3607.